The motor neuron disease treatment market is witnessing substantial growth, primarily fueled by the rising incidence of conditions like Amyotrophic L ...

Homeostatic plasticity, the brain's method of preserving equilibrium in neural circuits, relies heavily on spontaneous ...

Background Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited. Methods This retrospective ...

Glioblastoma Awareness Day 2025 is observed to raise awareness and educate people about glioblastoma the most common and ...

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Anti-NMDA Receptor Encephalitis is a rare brain condition that can be mistaken for the flu or a psychiatric illness Here’s ...

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

A California man was diagnosed with Anti-NMDA receptor encephalitis, a rare autoimmune brain disorder often mistaken for ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

Glaucoma represents a critical challenge in ocular medicine as one of the leading causes of irreversible blindness. Traditional therapies primarily focus on ...

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc.

Figure 2. Demonstration of N -methyl- D -aspartate receptor antibodies in the patient's cerebrospinal fluid. (A,B) Sagittal section of rat hippocampus incubated with the patient's cerebrospinal ...